LAS VEGAS--(BUSINESS WIRE)--April 5, 2004--Laredo Investment Corporation (LRDI) (OTCBB: LRDI) announced today its’ private label manufacturing facility (formerly GFR Nutritionals Ltd.) will now be known as GFR Pharma Ltd. This will pave the way for the expansion of their product line to include pharmaceutical products and the corresponding improvements to their cGMP (current Good Manufacturing Practices) facility.
According to Richard Pierce, President and CEO, “The strengths that people have come to recognize in GFR will remain. We will be providing the same personalized service on which we have built our reputation in the industry only now we will be offering a greater range of quality products.”
The company’s wholesale division, R&L Health Inc. will now be known as GFR Health Ltd. This change will allow GFR Health products to benefit from the branding of the GFR name while making interactions seamless for the customer.
GFR Pharma Ltd. is a full service, private label, cGMP manufacturing facility specializing in the production of OTC products as well as natural source nutritional, herbal and sports nutrition products. They manufacture tablets, capsules and powders and provide formulating, blending, packaging, product testing, technical support, market research, label design and regulatory information.
GFR Pharma Ltd. is the licensed distributor of SoyFerm(R), an organic, naturally fermented whole food soy powder.
GFR Health Ltd. is the wholesale division, which researches, develops, and markets the trademarked nutraceutical health products WheyProtein, ReCleanse(R), and Lean Fit(TM).
Certain of these statements contained in this press release may be deemed forward-looking statements. Such statements, and other matters addressed in this press release, involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from these statements and matters are the risks and other factors detailed, from time to time, in the Company’s reports with the Securities Exchange Commission, including, but not limited to, the Company’s Annual Reports on Form 10-K and its quarterly reports on Form 10-Q.
Contacts
Laredo Investment Corporation Richard Pierce, 604-460-8440 ext. 222 or Toll Free: 877-560-8440 Email: rpierce@gfrpharma.com